Oveporexton approved for narcolepsy: Restoring the brain’s missing wakefulness signal
-
-
REFERENCES
[1] Mahoney, C.E., Cogswell, A., Koralnik, I.J. et al. (2019). The neurobiological basis of narcolepsy. Nat. Rev. Neurosci. 20:83−93. DOI:10.1038/s41583-018-0097-x [2] Vassalli, A., Tafti, M., and Liblau, R.S. (2026). Narcolepsy is (not) an autoimmune disease. Nat. Rev. Neurol. 22:519−531. DOI:10.1038/s41582-026-01232-9 [3] Dauvilliers, Y., Plazzi, G., Mignot, E., et al. (2025). Oveporexton, an oral orexin receptor 2-selective agonist, in narcolepsy type 1. N. Engl. J. Med. 392:1905−1916. DOI:10.1056/NEJMoa2405847 [4] Mignot, E., Dauvilliers, Y., Del Rio Villegas, R., et al. (2026). Efficacy and safety of oveporexton (TAK-861), an oral orexin receptor 2 agonist, for narcolepsy type 1 treatment: A pooled analysis of Phase 3 studies. Sleep 49 (Suppl. 1) :A328–A329. DOI: 10.1093/sleep/zsag091.0736 [5] Dauvilliers, Y., Mignot, E., Del Rio Villegas, R., et al. (2023). Oral orexin receptor 2 agonist in narcolepsy type 1. N. Engl. J. Med. 389:309−321. DOI:10.1056/NEJMoa2301940 -
ABOUT THIS ARTICLE
Cite this article:
The Innovation News Team (2026). Oveporexton approved for narcolepsy: Restoring the brain’s missing wakefulness signal. The Innovation Neurology 1:100013. https://doi.org/10.59717/j.xinn-tine.2026.100013
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
The Innovation News Team (2026). Oveporexton approved for narcolepsy: Restoring the brain’s missing wakefulness signal. The Innovation Neurology 1:100013. https://doi.org/10.59717/j.xinn-tine.2026.100013
Format
Content
DownLoad:
-
Figure 1.
ORZEYFUL (oveporexton) approved for the treatment of narcolepsy type 1
